OBJECTIVE: The aims of this study were to appraise the predictive value of variations in a single-nucleotide polymorphism (SNP) in the low-density lipoprotein receptor (LDLR) gene for sustained virological response (SVR) to pegylated interferon (Peg-IFN) and ribavirin (RBV), as well as to analyze the relationship between LDLR genotype and other predictors of SVR, particularly IL28B genotype, in patients coinfected with HIV and hepatitis C virus (HCV). METHODS: One hundred and eighty-four HIV/HCV-coinfected, treatment-naive patients with chronic HCV infection, who received Peg-IFN and RBV, were included. Variations in the SNP rs14158 and rs12979860 were tested by Taqman PCR assay. RESULTS: Twenty-eight (38%) patients with rs14158 TT/TC and 61 (55%) with CC (P = 0.028) achieved SVR. The rates of SVR in patients with rs14158 TT/TC and with CC harboring HCV 1-4 were 20 and 41% (P = 0.020), respectively, and, in those with HCV genotype 2-3, 75 and 84% (P = 0.513), respectively. Patients with rs14158 CC showed less commonly plasma HCV-RNA load at least 600000 IU/ml (57 vs. 71%, P = 0.047) and lower likelihood of relapse (13 vs. 30%, P = 0.023). In patients with HCV genotype 1-4, the rates of SVR according to the combination of IL28B/LDLR genotypes were: CC/CC = 69%; CC/non-CC: 30%; non-CC/CC: 25%; non-CC/non-CC: 14% (P < 0.001). CONCLUSION: Variations in rs14158 are associated with SVR to Peg-IFN and RBV in HIV/HCV-coinfected patients harboring HCV genotype 1-4. LDLR and IL28B genotypes seem to have a synergistic effect on SVR. The combined use of LDLR and IL28B genotypes in routine clinical practice could enhance the predictive value of IL28B genotype alone.
OBJECTIVE: The aims of this study were to appraise the predictive value of variations in a single-nucleotide polymorphism (SNP) in the low-density lipoprotein receptor (LDLR) gene for sustained virological response (SVR) to pegylated interferon (Peg-IFN) and ribavirin (RBV), as well as to analyze the relationship between LDLR genotype and other predictors of SVR, particularly IL28B genotype, in patients coinfected with HIV and hepatitis C virus (HCV). METHODS: One hundred and eighty-four HIV/HCV-coinfected, treatment-naive patients with chronic HCV infection, who received Peg-IFN and RBV, were included. Variations in the SNP rs14158 and rs12979860 were tested by Taqman PCR assay. RESULTS: Twenty-eight (38%) patients with rs14158 TT/TC and 61 (55%) with CC (P = 0.028) achieved SVR. The rates of SVR in patients with rs14158 TT/TC and with CC harboring HCV 1-4 were 20 and 41% (P = 0.020), respectively, and, in those with HCV genotype 2-3, 75 and 84% (P = 0.513), respectively. Patients with rs14158 CC showed less commonly plasma HCV-RNA load at least 600000 IU/ml (57 vs. 71%, P = 0.047) and lower likelihood of relapse (13 vs. 30%, P = 0.023). In patients with HCV genotype 1-4, the rates of SVR according to the combination of IL28B/LDLR genotypes were: CC/CC = 69%; CC/non-CC: 30%; non-CC/CC: 25%; non-CC/non-CC: 14% (P < 0.001). CONCLUSION: Variations in rs14158 are associated with SVR to Peg-IFN and RBV in HIV/HCV-coinfectedpatients harboring HCV genotype 1-4. LDLR and IL28B genotypes seem to have a synergistic effect on SVR. The combined use of LDLR and IL28B genotypes in routine clinical practice could enhance the predictive value of IL28B genotype alone.
Authors: A Caruz; K Neukam; A Rivero-Juárez; R Herrero; L M Real; A Camacho; P Barreiro; P Labarga; A Rivero; J A Pineda Journal: Genes Immun Date: 2013-10-31 Impact factor: 2.676
Authors: A Rivero-Juarez; J A Mira; A Camacho; K Neukam; I Perez-Camacho; A Caruz; J Macias; J Torre-Cisneros; J A Pineda; A Rivero Journal: Infection Date: 2012-10-14 Impact factor: 3.553
Authors: P Monje-Agudo; A Castro-Iglesias; A Rivero-Juárez; F Martínez-Marcos; E Ortega-González; L M Real; B Pernas; N Merchante; P Cid; J Macías; M D Merino; A Rivero; A Mena; K Neukam; J A Pineda Journal: Eur J Clin Microbiol Infect Dis Date: 2015-07-09 Impact factor: 3.267
Authors: F A Di Lello; A Caruz; N I Rallon; A Rivero-Juarez; K Neukam; P Barreiro; A Camacho; S García-Rey; A Rivero; V Soriano; C Cifuentes; J Macias; J A Pineda Journal: Eur J Clin Microbiol Infect Dis Date: 2013-05-29 Impact factor: 3.267
Authors: Mostafa K El-Awady; Lotiaf Mostafa; Ashraf A Tabll; Tawfeek H Abdelhafez; Noha G Bader El Din; Naglaa Zayed; Reem El Shenawy; Yasmin El Abd; Reham M Hasan; Hosam Zaghlol; Hesham El Khayat; Ashraf O Abdel Aziz Journal: Hepat Mon Date: 2012-04-30 Impact factor: 0.660
Authors: Benjamin P Linas; Devra M Barter; Jared A Leff; Madeline DiLorenzo; Bruce R Schackman; Charles R Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Arthur Y Kim; Kenneth A Freedberg Journal: AIDS Date: 2014-01-28 Impact factor: 4.632
Authors: Antonio Rivero-Juarez; Rafael Gonzalez; Angela Camacho; Barbara Manzanares-Martin; Antonio Caruz; Antonio Martinez-Peinado; Julian Torre-Cisneros; Juan A Pineda; José Peña; Antonio Rivero Journal: PLoS One Date: 2013-04-16 Impact factor: 3.240
Authors: Antonio Rivero-Juarez; Luis F López-Cortés; Angela Camacho; Almudena Torres-Cornejo; Ana Gordon; Rosa Ruiz-Valderas; Julian Torre-Cisneros; Juan A Pineda; Pompeyo Viciana; Antonio Rivero Journal: PLoS One Date: 2014-06-19 Impact factor: 3.240